Trexam 250 mg/5 ml (IM/IV Injection)
5 ml ampoule: ৳ 40.00 (1 x 5: ৳ 200.00)
Medicine Details
Category | Details |
---|---|
Generic | Tranexamic acid |
Company | Healthcare pharmaceuticals ltd |
Also available as |
Title
- Trexam 500mg Tablets
- Tranexamic Acid Hemostatic Medication
Categories
- Medicine
- Healthcare
- Pharmacology
- Hemostasis
- Antifibrinolytic
- Antihemorrhagic
- Surgery
- Urology
- Obstetrics
- Oncology
- Stomatology
- Pharmacological Preparations
Description
- Used for prophylaxis and therapy of various hemorrhagic conditions
- Shows antifibrinolytic action
- 10 times more active than conventional hemostatics
- Effective in hemoptysis, digestive hemorrhages, leukaemia, cirrhosis, hemophilia, thrombocytopenic purpura, post-operative and traumatic shock, etc.
- Well absorbed by oral route with effect seen in 15-30 minutes
- Excreted mainly by renal route
- Low acute and chronic toxicity
- No interference with clotting processes
- Incompatible with penicillins, thrombolytic drugs, and estrogen-containing medications
- Contraindicated in thromboembolic disease, serious kidney failure, and individual hypersensitivity
- Side effects may include fatigue, conjunctival irritation, nasal blockage, itching, skin reddening, exanthems, nausea, diarrhea, gastric pyrosis, and rare cases of postural hypotension
- Should not be administered during known and presumed pregnancy
- Passes into breast milk in low concentration
- Prophylactic treatment should begin 24 hours before the operation and continue until 3-4 days after it
- Therapy of hemorrhages must be prolonged for at least 24 hours after manifestations have disappeared
- Particular care required in cardiopathic and hepatopathic subjects
- Belongs to therapeutic class of anti-fibrinolytic and haemostatic drugs
- Storage at 15-30°C in a dry place away from light and children's reach
Dimensions
- Tablets: 500mg
Color Options
- Not Applicable
Functions
- Prophylaxis and therapy of hemorrhagic conditions
- Antifibrinolytic action
- Inhibition of plasminogen activation
- No interference with clotting processes
Materials
- Tranexamic Acid (trans-4 aminomethyl-cyclohexanecarboxylic acid)
Technical Specifications
- 10 times more active than conventional hemostatics
- Low acute and chronic toxicity
- Well absorbed by oral route with effect seen in 15-30 minutes
- Excreted mainly by renal route
- No interference with clotting processes
Design Elements
- Synthetic Amino Acid
- Intravenous and intramuscular administration
- Oral administration
- Slow intravenous route adminstration
Usability Features
- Prophylactic treatment must begin 24 hours before the operation and continue until 3-4 days after it
- Therapy of hemorrhages must be prolonged for at least 24 hours after manifestations have disappeared
- Particular care required in cardiopathic and hepatopathic subjects
- Storage at 15-30°C in a dry place away from light and children's reach